Sam Eldessouky

October 8, 2026

BLCO Advances Oral Dry AMD Treatment After FDA Meeting. Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.

October 17, 2026

TE Connectivity Q3 Beat Highlights Dividend Strength. TE Connectivity recently reported better-than-expected third-quarter earnings, surpassing analyst estimates. The company's performance was positive, but it has relatively low exposure to the artificial intelligence sector. Additionally, there are concerns about potential competition from coherent photonics technology. Despite these challenges, TE Connectivity maintains a dividend yield of 1.80%, which supports its appeal to income-focused investors.

October 12, 2026

BHC appoints interim CEO and looks to raise FY26 EBITDA guidance. Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.